Mabwell (688062.SH): 9MW2821 will present clinical data in an oral presentation at the 2026 ESMO Congress.

Mabwell (688062.SH) announced that, at the 2026 European Society for Medical Oncology (ESMO) Congress to be held in Madrid, Spain, from October 23 to October 27, 2026, the company will present in an oral presentation Phase II clinical study data for its innovative Nectin-4-targeting ADC in patients with locally advanced or metastatic triple-negative breast cancer (TNBC) who had previously received ADC therapy with a topoisomerase I inhibitor payload: As of April 10, 2026, among 60 efficacy-evaluable patients, the objective response rate (ORR) was 30.0%, the disease control rate (DCR) was 80.0%, the median progression-free survival (mPFS) was 3.7 months, the median duration of response (mDOR) was 8.7 months, and median overall survival (mOS) had not yet matured. No new safety signals were observed during this follow-up period.